CVS Health (CVS) stock soared about 15% yesterday after posting upbeat fourth-quarter results, with revenues and earnings ...

Deutsche Bank raised the firm’s price target on CVS Health (CVS) to $70 from $66 and keeps a Buy rating on the shares. The company issued a ...

Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...

CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...

Languages: English. You can get in touch with Joe by emailing [email protected] Multiple recalls for products on CVS Pharmacy shelves were recently initiated due to risk of microbial ...

CVS Health CEO David Joyner sees a way to create a more efficient healthcare professional network under the CVS umbrella. For the second day in a row, CVS Health's (NYSE: CVS) stock price saw a ...

California Gov. Gavin Newsom and state legislators in Sacramento seem to agree: Prescription drug prices are too high.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After eight years of growth, the market still is thriving. Further, most specialty contractors believe it will continue to improve through the end of 2018 and have backlogs to prove it.

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Rockwool A/S Series A 4.09% kr.60.3B Rockwool A/S Series B 3.54% kr.60.3B ...

After hours: February 7 at 7:44:34 PM EST ...